FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

NEXT STORY
AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders
PREV STORY
New To The Street / Newsmax TV Announces 8 Interviews for This Week’s Broadcast, Sunday, August 08, 2021, Hour Slot 10-11 AM ET
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn’s disease in Europe

PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval ...

author_avatar
NASDAQ Market News

Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

Achieved positive results in Phase 3 EPIC and CARE clinical trials of plazomicin; NDA ...

author_avatar
NASDAQ Market News

Tesaro Announces Participation in Three Investor Conferences

WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

author_avatar
NASDAQ Market News